nu6102 and purvalanol a

nu6102 has been researched along with purvalanol a in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M	1
Jarhad, DB; Jeong, LS; Kim, HR; Mashelkar, KK; Noh, M	1
Bacevic, K; Boszonyik, B; Fisher, D; Hochberg, ME; Krasinska, L; Noble, R; Prieto, S; Soffar, A; Vincent, C; Wael Ammar, O	1

Reviews

1 review(s) available for nu6102 and purvalanol a

Article	Year
Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics. Journal of medicinal chemistry, 2018, 11-21, Volume: 61, Issue:22 Topics: Animals; Biological Products; Disease; Dyrk Kinases; Enzyme Activation; Humans; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases	2018

Other Studies

2 other study(ies) available for nu6102 and purvalanol a

Article	Year
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51 Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases	2007
Spatial competition constrains resistance to targeted cancer therapy. Nature communications, 2017, 12-08, Volume: 8, Issue:1 Topics: Animals; Antineoplastic Agents; Cell Culture Techniques; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Nude; Models, Biological; Neoplasms; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; RNA, Small Interfering; Spheroids, Cellular; Tumor Burden; Xenograft Model Antitumor Assays	2017

Article

Year

A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.

Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51

Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases

2007

Spatial competition constrains resistance to targeted cancer therapy.

Nature communications, 2017, 12-08, Volume: 8, Issue:1

Topics: Animals; Antineoplastic Agents; Cell Culture Techniques; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Nude; Models, Biological; Neoplasms; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; RNA, Small Interfering; Spheroids, Cellular; Tumor Burden; Xenograft Model Antitumor Assays

2017